Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM. Martin M, et al. Among authors: furio v. Breast Cancer Res Treat. 2011 Jul;128(1):127-36. doi: 10.1007/s10549-011-1461-y. Epub 2011 Apr 5. Breast Cancer Res Treat. 2011. PMID: 21465170 Clinical Trial.
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. Martín M, et al. Among authors: furio v. Breast Cancer Res Treat. 2013 Apr;138(2):457-66. doi: 10.1007/s10549-013-2416-2. Epub 2013 Feb 20. Breast Cancer Res Treat. 2013. PMID: 23423445 Free PMC article.
Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.
Romero A, Prat A, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M. Romero A, et al. Among authors: furio v. Clin Transl Oncol. 2014 Apr;16(4):386-94. doi: 10.1007/s12094-013-1088-z. Epub 2013 Aug 2. Clin Transl Oncol. 2014. PMID: 23907291 Clinical Trial.
18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.
García García-Esquinas M, García-Sáenz JA, Arrazola García J, Enrique Fuentes Ferrer M, Furió V, Rodriguez Rey C, Román JM, Carreras Delgado JL. García García-Esquinas M, et al. Among authors: furio v. Q J Nucl Med Mol Imaging. 2014 Mar;58(1):66-73. Epub 2013 Oct 9. Q J Nucl Med Mol Imaging. 2014. PMID: 24104854
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A. Albanell J, et al. Among authors: furio v. Ann Oncol. 2012 Mar;23(3):625-631. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6. Ann Oncol. 2012. PMID: 21652577 Free article.
51 results